GlaxoSmithKline
Scientific Office

جلاكسو سميث كلاين
المكتب العلمي

ترخيص رقم 00047 – 59 - 32 - 101
رقم العضوية 68583

July 20, 2014

Title: ARZERRA® (ofatumumab) – change to safety information regarding update to hepatitis B virus reactivation warning

Dear Healthcare Professional,

GlaxoSmithKline would like to inform you of an important change to the safety information of ARZERRA® regarding risk of hepatitis B virus (HBV) reactivation in patients receiving CD20-directed cytolytic antibodies, including ARZERRA®, in some cases resulting in fulminant hepatitis, hepatic failure, and death.

Summary:

- Boxed Warning about the risk of hepatitis B virus (HBV) reactivation, which states "Hepatitis B Virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, including ARZERRA®, in some cases resulting in fulminant hepatitis, hepatic failure, and death."
- The Warnings and Precautions section of the prescribing information to be expanded to include recommendations for screening, monitoring and management of HBV reactivation after Saudi Food and Drug Authority (SFDA) approval.
- HCPs should screen all patients for HBV infection before starting ARZERRA®.

Action required by Health Care Providers/Investigators

Healthcare professionals should follow the recommendations below:

- Screen all patients for HBV infection before starting ARZERRA® by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc).
- Patients with active/current hepatitis B infection should not be treated with ofatumumab.
- For patients who show evidence of hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy.
- Monitor patients with evidence of prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during therapy with ARZERRA® and for several months after completion of therapy with ARZERRA®.

- In patients who develop reactivation of HBV while receiving ARZERRA®, immediately discontinue ARZERRA® and any concomitant chemotherapy, and institute appropriate treatment. Resumption of ARZERRA® in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing hepatitis B. Insufficient data exist regarding the safety of resuming ARZERRA® in patients who develop HBV reactivation.

Healthcare professionals are reminded of the risk of HBV infection and hepatitis in patients who have not been previously exposed to HBV

Further Information

A recent review of anti-CD20 monoclonal antibody treatment has shown that in patients treated with medicines classified as CD20-dyrected cytolytic antibodies, including ofatumumab, HBV reactivation and infection occurred, which in some cases resulted in fulminant hepatitis, hepatic failure and death.

Cases of HBV infection and virus reactivation have been reported in patients with a positive surface antigen (HBsAg) as well as in those with positive hepatitis b "core" antibody (anti-HBc) that were HBsAg negative. The reactivation occurred in patients where HBV infection was apparently cured (that is HBsAg negative, anti-HBc positive and positive antibodies for hepatitis B surface antigen).

Revised Labeling

Local prescribing information to be updated to reflect the new safety update after taking the SFDA approval.

The letter is sent in agreement with the Saudi Food and Drug Authority

Call for reporting

GlaxoSmithKline will continue to monitor the safety of **ARZERRA® (ofatumumab)** and update SFDA of any serious adverse event for evaluation. You can assist us in monitoring the safety of **ARZERRA® (ofatumumab)** by reporting adverse reactions to fax: +966 12 6536660 or by email to GlaxoSmithKline safety email: faisal.m.shujrah@gsk.com Or to the National Pharmacovigilance and Drug Safety Center at Fax: +966 11 2057662 or by email to: npc.drug@sfda.gov.sa

If you have any question about the new information, please contact GSK medical information department at GlaxoSmithKline Saudi Arabia by phone: +966 12 6536666 or fax: +966 12 6536660.

Best regards

P.P.

Nauman Rashid
Medical Director
GlaxoSmithKline
Saudi Arabia